...A. Growth is accelerating as we've seen coming out of late '23 through '24. B. We had 4% constant currency revenue growth. C. We beat our guidance ranges on both the revenue, adjusted EBITDA as well as the adjusted EPS lines. D. We raised our revenue guidance on the FX assumptions that we saw. E. We saw good quality growth really across Farm Animal, Pet Health, both price and volume. F. On the innovation side, we raised guidance again up to the $660 million to $740 million range. G. I would point out three that really do matter a lot and are really contributors in Q1 and to our guidance confidence on this innovation, and that is Quattro, no question; Experior, we define that as now a $350 million potential market in North America; and Adtab. H. And then cash, we announced on earnings week actually monetizing our royalties on the lotilaner asset, bringing in just shy of $300 million that will go to delevering. I. We now have a clear path, good operating results, more EBITDA, free cash flow...
